Taienkang (301263.SZ) subsidiary received a registration certificate for finasteride tadalafil capsules

According to Zhitong Finance App, Taienkang (301263.SZ) announced that Shandong Huabo Kaisheng Biotechnology Co., Ltd. (“Huabo Kaisheng”), a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for finasteride tadalafil capsules issued by the State Drug Administration. According to the data on the website of the State Drug Administration, up to now, no other domestic company has obtained a drug registration certificate for finasteride tadalafil capsules. Huabo Kaisheng is the first domestic company to obtain a drug registration certificate.

Finasteride tadalafil capsules are a compound preparation composed of finasteride (a 5α-reductase inhibitor) and tadalafil (a phosphodiesterase 5 (PDE5) inhibitor), specifically designed to treat the signs and symptoms of benign prostatic hyperplasia (BPH, or prostatic hypertrophy) in men. The two form a synergistic therapeutic effect through different mechanisms of action: finasteride can reduce prostate volume and improve urination difficulties, while tadalafil can directly relieve lower urinary tract symptoms associated with BPH. At the same time, since tadalafil has the effect of improving erectile function, it can also target and eliminate adverse effects of erectile dysfunction that may be caused by finasteride medication.